Physician profile
Mark S Williams
NPI 1477554624
$2,406.80
in general payments reported to CMS, 2019-2025
37 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $322 · 2021: $487 · 2022: $538 · 2023: $160 · 2024: $325 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $323.49 | 2019-2022 | |
| Amgen INC. | $321.88 | 2019-2025 | Evenity |
| Merck Sharp & Dohme LLC | $216.07 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $201.53 | 2020-2022 | |
| Stryker Corporation | $198.33 | 2022-2024 | Triathlon, Mako, Tritanium |
| Globus Medical, INC. | $159.00 | 2025 | Stelkast Generic Knee Instruments |
| Abbott Laboratories | $139.07 | 2021-2022 | |
| Vertos Medical, INC. | $138.34 | 2023-2024 | Mild Device Kit |
| Foundation Fusion Solutions, LLC | $75.29 | 2023-2024 | |
| Pfizer INC. | $40.42 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.84 | 2022 | |
| Biotronik Nro, INC. | $39.24 | 2024 | Prospera |
| Endo Pharmaceuticals INC. | $38.79 | 2019 | |
| Lilly USA, LLC | $35.62 | 2019 | |
| Abbvie INC. | $34.09 | 2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $32.31 | 2022 | |
| Glaxosmithkline, LLC. | $29.66 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $28.21 | 2022 | |
| Organogenesis INC. | $26.85 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.12 | 2021-2022 | |
| Esperion Therapeutics, INC. | $22.70 | 2021 | |
| Boston Scientific Corporation | $21.87 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $19.22 | 2023 | Iovera |
| Ferring Pharmaceuticals INC. | $19.07 | 2020 | |
| Almatica Pharma LLC | $17.22 | 2022 | |
| Optinose US, INC. | $15.61 | 2021 | |
| Nevro Corp. | $15.18 | 2024 | Senza |
| Pacira Therapeutics, INC. | $14.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.09 | 2020 | |
| Amarin Pharma, INC. | $13.88 | 2022 | |
| Nalu Medical, INC. | $13.75 | 2024 | Nalu Neurostimulation System |
| Novus Surgical Consultants | $13.56 | 2025 | |
| Sanofi-Aventis U.S. LLC | $13.29 | 2022 | |
| Siemens Medical Solutions USA, INC. | $12.57 | 2022 | |
| Bioventus LLC | $12.56 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.92 | 2019 | |
| Sanofi Pasteur INC. | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.